Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.

Autor:in

Eiring, A M; Page, B D G; Kraft, I L; Mason, C C; Vellore, N A; Resetca, D; Zabriskie, M S; Zhang, T Y; Khorashad, J S; Engar, A J; Reynolds, K R; Anderson, D J; Senina, A; Pomicter, A D; Arpin, C C; Ahmad, S; Heaton, W L; Tantravahi, S K; Todic, A; Colaguori, R; Moriggl, R; Wilson, D J; Baron, R; O'Hare, T; Gunning, P T; Deininger, M W

Dokumententyp

Korrektur

DOI

10.1038/leu.2017.14

PubMed ID

28465516